
CAS 1446090-79-4
:Formule :C25H17F3N4O3
InChI :InChI=1S/C25H17F3N4O3/c26-25(27,28)11-1-4-15-16(9-11)31-24(30-15)21-20-14-10-12(2-5-17(14)35-22(20)21)34-18-7-8-29-23-13(18)3-6-19(33)32-23/h1-2,4-5,7-10,20-22H,3,6H2,(H,30,31)(H,29,32,33)/t20-,21-,22-/m0/s1
Code InChI :NGFFVZQXSRKHBM-FKBYEOEOSA-N
SMILES :C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)O[C@H]5[C@@H]4[C@@H]5C6=NC7=C(N6)C=C(C=C7)C(F)(F)F
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
6 produits trouvés.
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
Lifirafenib
CAS :Formule :C25H17F3N4O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :478.4227Lifirafenib
CAS :5-(((1R,1aS,6bR)-1-(6-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-oneFormule :C25H17F3N4O3Degré de pureté :98%Masse moléculaire :478.42Lifirafenib
CAS :Lifirafenib is a potent and selective kinase inhibitor, which is synthetically derived. It operates by targeting and inhibiting specific pathways involving the RAF kinases within the MAPK/ERK signaling cascade. This interruption is critical in the control of cellular proliferation and survival, pathways often dysregulated in various cancers. Lifirafenib is particularly effective against BRAF-mutant cancers, including melanoma and certain types of thyroid and colorectal cancers.Formule :C25H17F3N4O3Degré de pureté :Min. 95%Masse moléculaire :478.42 g/molLifirafenib
CAS :Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinantFormule :C25H17F3N4O3Degré de pureté :97.99% - 98%Couleur et forme :SolidMasse moléculaire :478.4227





